Role of ormeloxifene in the management of dysfunctional uterine bleeding: a prospective study

Sharda B. Ahmed, Sushma Mogri, Shivani Barala


Background: Menorrhagia is an important healthcare problem and most common indication for hysterectomies worldwide. This study was carried out to assess the efficacy, safety and acceptability of Ormeloxifene in the medical management of Dysfunction uterine bleeding (DUB).

Methods: For the study 50 women aged 27-48 years who attended the outpatient gynecology department in a tertiary care hospital with complaint of heavy menstrual flow were recruited. Ormeloxifene (60 mg) was given orally twice a week for first 12 weeks and then once a week for up to next 12 weeks. The primary outcome measures were reduction in menstrual blood loss which was measured by fall in PBAC (Pictorial blood assessment chart) score, rise in hemoglobin level and reduction in endometrial thickness.

Results: The reduction in mean PBAC score at the end of 12th week was found to be statistically significant (P<0.001). There was also significant decrease in the mean endometrial thickness (P<0.001) after treatment with Ormeloxifene when compared to mean baseline value. The difference in mean hemoglobin level is 1.96 gm/dl between baseline and post treatment level was found to be statistically significant (P<0.001). No major adverse effects were experienced by patients in this study.

Conclusions: Ormeloxifene is very effective and safe alternative in the management of dysfunction uterine bleeding. It has a good patient acceptability and compliance due to its minimal side effects, low cost and simple dosag


Dysfunctional Uterine Bleeding, Menorrhagia, Ormeloxifene

Full Text: